IL-27 Antibody
Code | Size | Price |
---|
PSI-3797-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3797-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
IL-27 Antibody: p28, IL30, IL-27, IL27A, IL-27A, IL27p28, Interleukin-27 subunit alpha, p28, IL-27 subunit alpha
Application Note:
WB: 0.5 - 4 μg/mL; ICC: 10 μg/mL.
Antibody validated: Western Blot in human and mouse samples; Immunocytochemistry in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human and mouse samples; Immunocytochemistry in mouse samples. All other applications and species not yet tested.
Background:
IL-27 Antibody: Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of na?ve but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet.
Background References:
- Hunter et al. Nat. Rev. Immunol. 2005; 5:521-31.
- Pfanz et al. J. Immunol. 2004; 172:2225-31.
- Hisada et al. Cancer Res. 2004; 64:1152-6.
Buffer:
IL-27 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rat: (63%)
Immunogen:
Anti-IL-27 antibody (3797) was raised against a peptide corresponding to 16 amino acids near the amino terminus of human IL-27.
The immunogen is located within the first 50 amino acids of IL-27.
The immunogen is located within the first 50 amino acids of IL-27.
ISOFORMS:
Human IL-27 has one isoform (243aa, 28kD). Mouse IL-27 has one isoform (234aa, 27kD) and rat IL-27 also has one isoform (234aa, 27kD). 3797 can detect human, mouse and rat IL-27.
NCBI Gene ID #:
246778
NCBI Official Name:
interleukin 27
NCBI Official Symbol:
IL27
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 28 kDa
Observed: 28 kDa
Observed: 28 kDa
Protein Accession #:
NP_663634
Protein GI Number:
28416913
Purification:
IL-27 Antibody is affinity chromatography purified via peptide column.
Research Area:
Immunology,Cancer
Swissprot #:
Q8NEV9
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:
Independent Antibody Validation in Cell lines (Figure 2) shows similar IL-27 expression profile in human and mouse cell lines detected by two independent anti-IL-27 antibodies that recognize different epitopes, 3797 against N-terminus domain and 3799 against central domain. IL-27 proteins are detected in the most tested cell lines at different expression levels by the two independent antibodies.
Recombinant Protein Test (Figure 3) shows that anti-IL-27 antibody (3797) detects human recombinant IL-17 (IL-17A + IL-17B) protein that contains the amino acids of 3797 antigenic peptide.
Related Products
Product Name | Product Code | Supplier | IL-27 Peptide | PSI-3797P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|